Table 2 Expression of T-cell priming markers based on microsatellite status (N = 440)a, tumor mutational burden (N = 450)b and programmed death ligand 1 expression, (N = 513)c (See Supplementary Table 1 for functions of T-cell priming markers).

From: T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

 

Microsatellite status

Tumor mutational burden (mutations/mb)

Programmed death ligand 1 expression

T-cell priming markers

Stable (N = 425)d

Unstable (N = 15)d

P value

<10 (N = 417)d

≥10 (N = 33)d

P value

<1% (N = 358)d

≥1% (N = 155)d

P value

CD27

45.4 (0–99)

60.1 (12–87)

0.051

42.9 (0–99)

45.5 (0–91)

0.61

43.1 (0–99)

50.3 (0–99)

0.008

CD28

43.9 (0–100)

39.7 (13–87)

0.58

41.4 (0–98)

33.9 (0–88)

0.13

44.6 (0–100)

40.8 (0–98)

0.16

CD40

46.3 (0–100)

44.1 (6–82)

0.77

45.1 (0–100)

33.0 (0–86)

0.019

44.2 (0–99)

50.4 (0–100)

0.022

CD40LG

44.3 (0–100)

45.1 (0–78)

0.92

41.2 (0–99)

35.6 (0–88)

0.28

45.1 (0–100)

40.0 (0–99)

0.076

CD80

48.5 (0–99)

62.3 (29–82)

0.057

46.2 (0–99)

50.2 (3–91)

0.42

46.4 (0–98)

53.2 (0–99)

0.010

CD86

42.6 (0–99)

57.5 (12–90)

0.042

40.8 (0–99)

43.2 (0–90)

0.63

41.2 (0–99)

47.3 (0–98)

0.021

CD137

40.8 (0–99)

56.7 (26–79)

0.031

38.4 (0–99)

45.2 (0–95)

0.17

37.5 (0–99)

49.4 (0–99)

<0.001e

GITR

46.3 (0–99)

54.1 (27–75)

0.29

45.3 (0–99)

46.2 (0–99)

0.86

42.0 (0–99)

55.3 (0–99)

<0.001e

GZMB

42.5 (0–99)

66.9 (6–98)

0.001e

39.9 (0–99)

55.5 (1–98)

0.002e

38.7 (0–98)

50.8 (0–99)

<0.001e

ICOS

36.2 (0–99)

43.9 (0–84)

0.32

33.2 (0–99)

36.5 (0–90)

0.53

32.5 (0–99)

42.4 (0–99)

<0.001e

ICOSLG

60.3 (0–99)

58.9 (21–96)

0.85

59.3 (0–100)

57.2 (0–98)

0.69

61.5 (0–100)

55.8 (0–99)

0.072

IFNG

29.3 (0–99)

60.5 (16–93)

<0.001e

27.4 (0–100)

44.0 (0–93)

<0.001e

25.2 (0–100)

40.5 (0–99)

<0.001e

OX40

50.5 (0–100)

59.9 (18–93)

0.18

48.7 (0–100)

51.2 (0–93)

0.60

49.2 (0–100)

53.8 (0–100)

0.10

OX40LG

44.4 (0–99)

44.8 (5–97)

0.96

44.0 (0–99)

35.1 (0–97)

0.11

45.5 (0–99)

41.9 (0–96)

0.22

TBX21

41.7 (0–99)

57.2 (15–80)

0.042

39.1 (0–99)

42.4 (0–99)

0.52

40.6 (0–98)

44.6 (0–99)

0.14

  1. CD Cluster of differentiation, GITR Glucocorticoid-Induced TNFR-Related, GZMB Granzyme B, ICOS Inducible T Cell Costimulator, IFNG Interferon-gamma, LG ligand, TBX T-Box Transcription Factor.
  2. a440 patients were evaluable for both T-cell priming marker expression and microsatellite status. 74 patients were not evaluated for microsatellite status.
  3. b450 patients were evaluable for both T-cell priming marker expression and tumor mutational burden. 64 patients were not evaluated for tumor mutational burden.
  4. c513 patients were evaluable for both T-cell priming marker expression and PD-L1 status. One patient had insufficient quality of PD-L1 testing.
  5. dMean and range of rank value of each gene expression are demonstrated. For instance, for patients with microsatellite stable, there are 425 patients and their mean rank value for CD27 expression was 45.4 and the range was 0–99. The rank value is based on the percentile.
  6. eSignificant p value (two-sided t-test) was defined as ≤0.003 (0.05/15 variables from T-cell priming markers) after Bonferroni correction. Transcript abundance was normalized to internal housekeeping gene profiles and ranked (0–100), standardized by internal reference population of 735 tumors spanning 35 histologies. See the Methods as well.
Back to article page